A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14673 participants.

Also called NCT02019264

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 14,673 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02019264
  • EudraCT 2013-000324-34
Other papers using this trial's data
  • Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients The New England journal of medicine, 2018-09-20 DOI, PubMed 30145941
  • Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial Lancet (London, England), 2018-11-24 DOI, PubMed 30293771
  • Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial Circulation, 2019-01-15 DOI, PubMed 30586726

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Chile, Mexico, New Zealand, Poland, Bahamas (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02019264. Randomized; double masking; primary purpose treatment. Start 2014-01-24 (actual); primary completion 2018-05-14 (actual). Results posted on 2019-07-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
Acronym
CAMELLIA-TIMI
Condition
Cardiovascular Disease
Condition
High Cardiovascular Risk
Condition
Obesity
Condition
Overweight
Intervention (Drug)
Lorcaserin hydrochloride
Intervention (Drug)
Placebo
Lead sponsor
Eisai Inc. (class: industry)
Collaborator
The TIMI Study Group (class: other)

Record details

Record id
cardio:ct-nct02019264
Content hash
d374e2a1972ac50f454eff27bc9c196e5d3121ca614ad51bc5aebb1eca6b9643